Excellent work & immense effort. But since the announcement of this LBA, I am not sure if the concept of this study is still applicable in the current era of IV DAC/Ven in patients unfit for SCT. The way I think about AML: pt fit for intensive chemo -> most likely fit for SCT.
-
-
-
Agree- I am surprised favorable risk was excluded as that would be the pt population I would think would benefit the most. This clearly cannot be extrapolated to non-intensive chemo strategies where HMA’s are continued indefinitely anyhow.
Kraj razgovora
Novi razgovor -
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.